MME and early-onset autosomal dominant Alzheimer disease: The engineered variant of NEP described here has significantly increased activity on and specificity towards Aβ, and therefore has potential to be a more efficacious therapeutic for Alzheimer’s disease with less activity on other peptides than wild-type NEP.